ArticleCell stem cell2018
METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m
Open access · bronzeAbstract read
In one paragraph
Article in Cell stem cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 665 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
665citing papers in PubMed, 1 pooled it
31.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
665 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,000 citations in OpenAlex.
- DNA methylation in monozygotic twins discordant for acute lymphoblastic leukemia: a case report and systematic review.Clinical epigenetics · 2025Pooled it
- Cell-cycle-driven noncanonical ubiquitination of METTL14 orchestrates RNA methylation.Nature chemical biology · 2026Article
- METTL14-Mediated m6A Modification of NEAT1_2 Releases YBX1 From Paraspeckles to Exacerbate Periodontitis.Journal of clinical periodontology · 2026Article
- RBM15 in leukemogenesis: an emerging regulator at the interface of RNA biology and hematopoiesis.Trends in cancer · 2026Review
- The N6-methyladenosine (mBritish journal of haematology · 2026Article
- RNA modifications as determinants of cancer cell death: from epitranscriptomic mechanisms to therapeutic targeting.Functional & integrative genomics · 2026Review
- PTBP1 controls oncogenic transcript processing and maintenance of acute myeloid leukemia.Leukemia · 2026Article
- RNA terminal uridylyl transferases are druggable vulnerabilities in AML but are dispensable for normal hematopoiesis.Science advances · 2026Article
- m6A and NuRD complexes regulate monocytic differentiation and resistance to BCL2/BCL2L1 inhibitors in acute myeloid leukemia.Haematologica · 2026Article
- METTL14-dependent NExperimental & molecular medicine · 2026Article
- Interplay between N6-methyladenosine RNA methylation and protein lactylation: a novel crosstalk linking metabolism and epigenetic regulation in human diseases.Journal of translational medicine · 2026Review
- Article
- Methyltransferase-Like 14 Promotes the Angiogenesis of Hepatocellular Carcinoma via Targeting Vascular Endothelial Growth Factor A.Cancer reports (Hoboken, N.J.) · 2026Article
- Hepatitis B virus promotes hepatocellular carcinoma progression by disrupting NSUN2/YBX1-mediated mVirologica Sinica · 2026Article
- The crucial role of m6A methylation modification in nasopharyngeal carcinoma.Discover oncology · 2026Review
- YTHDF1 enhances ACSL3 translation in an m6A-dependent manner to regulate lipid metabolism and colorectal cancer progression.Translational cancer research · 2026Article
- miR-30c-2-3p Regulates METTL14 Expression and Inhibits Cell Migration in Breast Cancer.Current issues in molecular biology · 2026Article
- The impact of m6A modified cargo conveyed by exosomes on the tumor microenvironment.Discover oncology · 2026Review
- Review
- Unbiased profiling of translational landscape reveals TNFR2 as a translation-dependent vulnerability in colorectal cancer.Journal of experimental & clinical cancer research : CR · 2026Article
605 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
29 authors at 8 institutions in 2 countries.
Hengyou WengDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA.
Huilin HuangDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA.
Huizhe WuDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning 110122, China.
Xi QinDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA.
Boxuan Simen ZhaoDepartment of Chemistry, Department of Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago, Chicago, IL 60637, USA.
Lei DongDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA.
Hailing ShiDepartment of Chemistry, Department of Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago, Chicago, IL 60637, USA.
Jennifer SkibbeDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA.
Chao ShenDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA.
Chao HuDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA; Department of Hematology, The First Affiliated Hospital Zhejiang University, Hangzhou, Zhejiang 310003, China.
Yue ShengDepartment of Medicine and Cancer Research Center, The University of Illinois, Chicago, IL 60612, USA.
Yungui WangDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA; Department of Hematology, The First Affiliated Hospital Zhejiang University, Hangzhou, Zhejiang 310003, China.
Mark WunderlichDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Bin ZhangDepartment of Hematologic Malignancies Translational Science and Gehr Family Leukemia Center, City of Hope, Duarte, CA 91010, USA.
Louis C DoreDepartment of Chemistry, Department of Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago, Chicago, IL 60637, USA.
Rui SuDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA.
Xiaolan DengDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning 110122, China.
Kyle FerchenDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA.
Chenying LiDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA; Department of Hematology, The First Affiliated Hospital Zhejiang University, Hangzhou, Zhejiang 310003, China.
Miao SunDivision of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Zhike LuDepartment of Chemistry, Department of Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago, Chicago, IL 60637, USA.
Xi JiangDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA.
Guido MarcucciDepartment of Hematologic Malignancies Translational Science and Gehr Family Leukemia Center, City of Hope, Duarte, CA 91010, USA.
James C MulloyDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Jianhua YangKey Laboratory of Gene Engineering of the Ministry of Education, Sun Yat-sen University, Guangzhou 510275, China.
Zhijian QianDepartment of Medicine and Cancer Research Center, The University of Illinois, Chicago, IL 60612, USA.
Minjie WeiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning 110122, China. Electronic address: mjwei@hotmail.com.
Chuan HeDepartment of Chemistry, Department of Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, Howard Hughes Medical Institute, University of Chicago, Chicago, IL 60637, USA. Electronic address: chuanhe@uchicago.edu.
Jianjun ChenDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA. Electronic address: jianchen@coh.org.
University of Cincinnati · USHoward Hughes Medical Institute · USCincinnati Children's Hospital Medical Center · USZhejiang Cancer Hospital · CNCity of Hope · USUniversity of Illinois Chicago · USChina Medical University · CNSun Yat-sen University · CN
Funding
Transcriptome-wide base-resolution sequencing of pseudouridine in human normal and AD brain tissues-CEGS Admin supplement 2020-2021RM1HG008935 · NHGRI · UNIVERSITY OF CHICAGO · PI HE, CHUAN · 2016 to 2025
$24.4MTargeting FTO to treat acute myeloid leukemiaR01CA243386 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2020 to 2024
$2.8MThe role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AMLR01CA236399 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2019 to 2023
$2.3MTargeting TET1 signaling to treat acute myeloid leukemiaR01CA211614 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2017 to 2021
$2.3MThe role and mechanism of FTO in leukemogenesis and drug responseR01CA214965 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2017 to 2021
$2.1MTherapeutic insights through patient derived leukemia xenograftsR50CA211404 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI Mark Wunderlich · 2016 to 2026
$1.9MPotential therapeutic implications of targeting miR-150 in acute myeloid leukemiaR01CA182528 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2014 to 2018
$1.7MThe role and functional mechanism of TET1 in MLL-rearranged leukemiaR01CA178454 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2014 to 2018
$1.7MThe role of EVI1-induced hypermethylation in leukemogenesis.R01HL131444 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI QIAN, ZHIJIAN · 2016 to 2019
$1.6MThe molecular mechanism of clonal dominance in 5q(del) MDSR01DK107615 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI QIAN, ZHIJIAN · 2016 to 2019
$1.4MHoward Hughes Medical InstituteNCI NIH HHS R01 CA178454NCI NIH HHS R01 CA182528NCI NIH HHS R01 CA211614NCI NIH HHS R01 CA214965NCI NIH HHS R01 CA236399NCI NIH HHS R01 CA243386NCI NIH HHS R50 CA211404NHGRI NIH HHS RM1 HG008935NHLBI NIH HHS R01 HL131444NIDDK NIH HHS R01 DK107615
Abstract
N
Indexed as
Cell DifferentiationAdenosineAnimalsCarcinogenesisCell ProliferationCell SurvivalDown-RegulationGene Expression Regulation, LeukemicHEK293 CellsHematopoietic Stem CellsHumansLeukemia, Myeloid, AcuteMethyltransferasesMice, Inbred C57BLMyeloid CellsNeoplastic Stem CellsAdenosineMethyltransferasesMETTL14 protein, humanMettl14 protein, mouseN-methyladenosineProto-Oncogene ProteinsProto-Oncogene Proteins c-mybProto-Oncogene Proteins c-mycProto-Oncogene Protein Spi-1RNA, MessengerTrans-Activatorsacute myeloid leukemiaHSCHSPCsLSCs/LICsMETTL14MYBMYCmyeloid differentiation blockN(6)-methyladenosine modificationSPI1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.